IL31 and prurigo nodularis: Vixarelimab is a monoclonal antibody being developed for the treatment pf prurigo nodularis by Kiniksa Pharmaceuticals Corp; it simultaneously targets both the OSMRβ, which mediates signaling of IL-31, and the oncostatin M pathways (105).